Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 45 for:    colon cancer | ( Map: Hawaii, United States )

Oncology Episode Payment Model in Hawaii

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03523546
Recruitment Status : Active, not recruiting
First Posted : May 14, 2018
Last Update Posted : December 12, 2018
Sponsor:
Collaborator:
Hawaii Medical Service Association
Information provided by (Responsible Party):
Amol Navathe, University of Pennsylvania

Brief Summary:
The HMSA Cancer Episode Payment Model (CEM) is a payment model designed to test the effects of better care coordination on health outcomes and costs of care for Hawaii Medical Services Association (HMSA) members with cancer who receive chemotherapy.

Condition or disease Intervention/treatment Phase
Breast Cancer Colon Cancer Lung Cancer Other: Cancer Episode Payment Model (CEM) Not Applicable

Detailed Description:
The CEM is designed to improve community health, to improve care coordination, quality, and appropriateness of care, to improve patient experience, and to implement a value-based incentive structure that appropriately rewards oncologists for cost-savings and sustained of improved quality of care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Oncology Episode Payment Model in Hawaii
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cancer Episode Payment Model
Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
Other: Cancer Episode Payment Model (CEM)
Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.

No Intervention: Fee for Service
Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.



Primary Outcome Measures :
  1. Composite quality score [ Time Frame: 1 year ]
    Quality metrics included in the oncology model will be compared across the two arms.

  2. Episode cost [ Time Frame: 6 months ]
    Total spending of oncology patients in the episode will be compared across the two arms.

  3. Utilization of acute and specialty care [ Time Frame: 6 months ]
    Total utilization of acute and specialty care of oncology patients in the episode will be compared across the two arms


Secondary Outcome Measures :
  1. Quality of care at end of life [ Time Frame: 6 months ]
    Quality measures evaluating use of acute care and palliative care services at the end of life will be compared across the two arms

  2. Survival [ Time Frame: one year ]
    All cause mortality will be compared across the two arms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any oncologist who practices with Hawaii Oncology and is a participating provider.

Exclusion Criteria:

  • Any provider who does not practice with Hawaii Oncology.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03523546


Locations
Layout table for location information
United States, Hawaii
Hawaii Oncology
Honolulu, Hawaii, United States, 96701
Sponsors and Collaborators
University of Pennsylvania
Hawaii Medical Service Association

Layout table for additonal information
Responsible Party: Amol Navathe, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03523546     History of Changes
Other Study ID Numbers: 823981A
First Posted: May 14, 2018    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No